Advanced protection for high-risk groups — transplant, genetics and occupational risk

For certain patients, skin cancer is not an occasional concern but a persistent medical challenge. Organ transplant recipients, patients on long-term immunosuppressive therapy, and those with genetic predispositions or high-exposure occupations face a risk profile that standard prevention cannot fully address. ⁽¹⁾

For this cohort we use intensified, individualised protocols designed to manage a high rate of lesion formation and to prevent aggressive disease — choosing interventions by how strong the evidence is, not by how new or appealing they sound.

Looking for the general guide first? See How to reduce your skin cancer risk → for the foundations that apply to everyone.

1. Organ transplant and immunosuppression

When the immune system is suppressed to protect a transplanted organ, the skin’s immune surveillance falls with it. Transplant recipients develop squamous cell carcinoma (SCC) far more often than the general population, and these cancers can behave more aggressively, with a higher risk of recurrence and spread. ⁽¹⁾

The single highest-value step: review immunosuppression

The most effective lever in a transplant recipient is the immunosuppressive regimen itself. In the randomised TUMORAPA trial, switching from a calcineurin inhibitor to the mTOR inhibitor sirolimus reduced new cutaneous squamous cell carcinomas in kidney transplant recipients who had already had one (new SCC in 22% vs 39%; relative risk 0.56). ⁽²⁾

That benefit comes with more side effects, and some patients stop sirolimus because of them — so this is a whole-body decision made jointly with your transplant physician, balancing skin-cancer benefit against graft protection. Our role is to flag when skin-cancer burden is high enough to warrant the conversation. ⁽²⁾

Acitretin (oral retinoid)

For transplant recipients with a heavy burden of keratoses and keratinocyte cancers, low-dose acitretin reduces new skin cancers — in a placebo-controlled trial in renal transplant recipients, new SCCs occurred in 11% of the acitretin group versus 47% on placebo. ⁽³⁾ Acitretin requires monitoring (lipids, liver function) and is strictly avoided in pregnancy, so suitability is assessed individually.

Field therapy still works — but expect a blunted response

Field therapy clears precancerous actinic keratoses across an at-risk area rather than chasing single spots. Topical agents such as imiquimod partly rely on the local immune response, which systemic immunosuppression dampens — so clearance can be lower than in immunocompetent patients. Even so, a randomised study confirmed imiquimod can be used safely under systemic immunosuppression, and it remains useful alongside 5-fluorouracil and laser-assisted photodynamic therapy. ⁽⁴⁾ In practice we often plan for repeated rounds.

2. Genetic predisposition and syndromes

Some patients are born with a reduced capacity to repair UV-induced DNA damage or an inherited tendency to tumour formation.

• Strong melanoma family history or many atypical moles raises baseline risk. We manage this with structured digital surveillance and full-body mapping to detect change at the earliest possible stage — see life after a skin cancer diagnosis →.
• Genetic syndromes such as Gorlin (nevoid basal cell carcinoma) syndrome can cause numerous basal cell carcinomas — sometimes dozens or hundreds over a lifetime — and require a proactive, surgery-sparing, multi-modal plan. ⁽⁹⁾

These patients benefit from coordinated care, careful sun protection from a young age, and an emphasis on the least-destructive effective treatment for each lesion.

3. Occupational risk for outdoor workers

If you work outdoors, your cumulative UV exposure is substantially higher than an indoor worker’s, and occupational solar UV is an established risk factor for squamous cell carcinoma — a systematic review and meta-analysis found roughly double the risk. ⁽⁸⁾ Chronic, long-term exposure drives extensive “field” damage across the face, scalp, neck, ears and hands.

• Physical protection first. Sunscreen alone is often insufficient across a full shift because it is sweated or rubbed off. Loose, long-sleeved UPF 50+ clothing and a broad-brim hat provide a barrier that does not fail mid-shift — see sun protection beyond sunscreen →.
• Reapply realistically. Where skin is uncovered, sunscreen must be reapplied every two hours and after sweating.
• Regular checks. A high cumulative dose justifies scheduled professional skin checks rather than waiting for a noticeable lesion.

How we build a high-risk protocol

We don’t rely on a single tool. For the highest-risk patients we combine the steps that have the strongest evidence:

• Medication review — for transplant patients, discuss immunosuppression (including an mTOR-inhibitor switch) with the transplant team. ⁽²⁾
• Field clear-outs — scheduled topical field therapy or laser-assisted PDT, accepting that multiple rounds may be needed. ⁽⁴⁾
• Acitretin — considered for a heavy keratinocyte-cancer burden in transplant recipients. ⁽³⁾
• Intensive surveillance — professional reviews every 3–6 months, with digital mapping where appropriate, to catch lesions before they become invasive.
• Rigorous sun protection — UPF 50+ clothing, hats, shade and the daily UV index — and a sensible vitamin D plan via diet and supplementation rather than deliberate sun exposure.

Emerging: the HPV vaccine (off label)

For selected patients with a high actinic-keratosis burden, the HPV vaccine is being studied off label. The 2025 VAXAK randomised trial (in immunocompetent AK patients) found the 9-valent HPV vaccine reduced AK lesion counts more than sham — a median 47% vs 29% reduction at 6 months (P = 0.01) and 58% vs 47% at 12 months (P = 0.05) — a real but modest extra benefit, with no demonstrated reduction in actual skin cancer at one year. ⁽⁷⁾ It is supplementary, not a substitute for the steps above — see Gardasil 9 for AK prevention →.

Book a high-risk skin check

If you are a transplant recipient, immunosuppressed, or otherwise at high risk, a structured skin check lets us assess your field damage and design an ongoing surveillance and prevention plan.